AG-1517 is an inhibitor of EGFR that displays anticancer properties. In vitro, this compound inhibits growth of cholangiocarcinoma cells. In keratinocytes, AG-1517 suppresses DNA replication, cell cycle progression, and cell proliferation, exhibiting potential benefit in the treatment of psoriasis.
| Cas No. | 153436-54-5 |
|---|---|
| Purity | ≥98% |
| Formula | C16H14BrN3O2 |
| Formula Wt. | 360.21 |
| IUPAC Name | N-(3-Bromophenyl)-6,7-dimethoxy-4-quinazolinamine |
| Synonym | Tyrphostin AG1517; PD153035; SU5271 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | A2501 Info Sheet PDF |
|---|
Zhang Z, Oyesanya RA, Campbell DJ, et al. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy. Hepatology. 2010 Sep;52(3):975-86. PMID: 20607690.
Powell TJ, Ben-Bassat H, Klein BY, et al. Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors. Br J Dermatol. 1999 Nov;141(5):802-10. PMID: 10583160.
